文献速递泌尿男性生殖肿瘤

戈沙妥珠单抗治疗晚期尿路上皮癌:III期随机试验TROPiCS-04

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
PubMed 文献 · Ann Oncol · 2025-02-11

TROPiCS-04研究纳入711例经铂类化疗和检查点抑制剂治疗后进展的晚期尿路上皮癌患者,随机接受戈沙妥珠单抗(SG)或医生选择方案(TPC)。中位随访9.2个月,SG组与TPC组中位总生存期分别为10.3个月和9.0个月(HR 0.86,95%CI 0.73-1.02,P=0.087),差异未达统计学显著;SG组客观缓解率较高(23%对14%),但≥3级治疗相关不良事件和5级治疗中出现的不良事件发生率更高。

要点

  • SG组与TPC组中位OS分别为10.3个月和9.0个月,HR 0.86(95%CI 0.73-1.02,P=0.087),未达统计学显著。
  • SG组与TPC组中位PFS分别为4.2个月和3.6个月(HR 0.86,95%CI 0.72-1.03),ORR分别为23%和14%。
  • SG组≥3级治疗相关不良事件发生率为67%,TPC组为35%;5级治疗中出现的不良事件发生率分别为7%和2%。

核心结论

  • 在经治晚期尿路上皮癌中,与TPC相比,SG未显著改善OS或PFS,但SG显示出较高的ORR。
  • SG的早期毒性相关并发症可能影响了疗效结局。

研究设计与样本

  • 全球开放标签随机III期TROPiCS-04研究(NCT04527991)。
  • 纳入经铂类化疗和检查点抑制剂治疗后进展的晚期尿路上皮癌患者,按1:1随机接受SG或TPC(紫杉醇、多西他赛或长春氟宁)。
  • 共随机711例患者;主要终点为总生存期(OS)。

主要发现

  • 中位随访9.2个月,SG组与TPC组中位OS分别为10.3个月和9.0个月(HR 0.86,95%CI 0.73-1.02,P=0.087),主要终点未达到。
  • SG组与TPC组中位PFS分别为4.2个月和3.6个月(HR 0.86,95%CI 0.72-1.03);ORR分别为23%(95%CI 18%-27%)和14%(95%CI 10%-18%)。
  • SG组最常见的≥3级治疗相关不良事件为中性粒细胞减少(35%,包括12%发热性中性粒细胞减少)。
  • SG组与TPC组≥3级治疗相关不良事件发生率分别为67%和35%;5级治疗中出现的不良事件发生率分别为7%和2%。
  • SG组25例5级治疗中出现的不良事件中16例为伴中性粒细胞减少的感染,多发生于治疗早期且具有多个发热性中性粒细胞减少危险因素的患者;SG组和TPC组初级预防性G-CSF使用率分别为21%和22%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We report the results from final analysis of the global open-label randomized phase III TROPiCS-04 study (NCT04527991) in pretreated aUC. PATIENTS AND METHODS: Patients with aUC whose disease had progressed on prior platinum-based chemotherapy and checkpoint inhibitor therapy were randomized 1 : 1 to receive SG or treatment of physician's choice (TPC; paclitaxel, docetaxel, or vinflunine). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and objective response rate (ORR) by investigator and blinded independent committee review, as well as safety. RESULTS: Overall, 711 patients were randomized. After a median follow-up of 9.2 months, the primary endpoint was not met [median OS for SG versus TPC: 10.3 months versus 9.0 months, hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.73-1.02, P = 0.087]. Median PFS with SG and TPC was 4.2 months and 3.6 months, respectively (HR 0.86, 95% CI 0.72-1.03); ORR (95% CI) was 23% (18% to 27%) and 14% (10% to 18%). The most common grade ≥3 treatment-related adverse event (TRAE) with SG was neutropenia (35%, including 12% with febrile neutropenia). Incidence of grade ≥3 TRAEs (67% versus 35%) and grade 5 treatment-emergent adverse events (TEAEs; 7% versus 2%) was higher with SG versus TPC. In the SG group, 16/25 grade 5 TEAEs were infections with neutropenia mostly occurring early in the treatment course of patients with multiple risk factors for febrile neutropenia. Primary prophylactic granulocyte colony-stimulating factor (G-CSF) usage with SG and TPC was 21% and 22%, respectively. CONCLUSIONS: SG did not result in a significant improvement in OS or PFS compared with TPC in pretreated aUC, although SG activity was demonstrated by a higher ORR. Early toxicity-related complications with SG may have impacted efficacy outcomes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Powles T, Tagawa S, Vulsteke C, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025. PMID: 39934055. doi:10.1016/j.annonc.2025.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。